ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
The burden of bone disease in Duchenne muscular dystrophy: age-specific prevalence of osteoporosis and low bone density.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Total body and appendicular lean mass by dual-energy X-ray absorptiometry are highly associated with muscle function and bone mineral density in Becker muscular dystrophy.Journal of neuromuscular diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated fracture and osteoporosis prevalence in a large cohort of children with DMD undergoing routine spine imaging. Osteoporosis is common and worsens with age and glucocorticoid use. Low total body bone mineral density may herald clinically detectable osteoporosis. Our findings emphasize the need for better detection and prevention.
introductionOsteoporosis is a major health concern in individuals with Duchenne muscular dystrophy (DMD) due to long-term glucocorticoid (GC) therapy, muscle weakness and restricted mobility. Osteoporosis results in long bone and vertebral fractures, which can lead to significant morbidity including premature loss of ambulation. We evaluated the age-related prevalence of osteoporosis and bone health indices in children and adolescents with DMD on daily GC therapy.
methodsWe conducted a retrospective review of patients with DMD seen at Cincinnati Children's Comprehensive Neuromuscular Center over 9 years. Bone health assessments included fracture history, routine annual spine radiographs and bone mineral density (BMD) by dual-energy X-ray absorptiometry.
resultsWe included 408 patients with DMD (mean age 8.0 ± 3.5 years, range 3.0-19.3 years) who had received daily GC (mean age of GC start 6.4 ± 2.5 years, mean duration 2.7 ± 2.4 years). Osteoporosis prevalence increased progressively with age: 4.4%, 20.9%, and 58.3% at ages 5, 10 and 18 years, respectively. The prevalence of long bone and/or vertebral fractures was 16.5%, 37.4%, and 83.3%, respectively. Low total body BMD Z-scores preceded clinically detectable osteoporosis, while low lumbar spine values lagged behind.
conclusionsOsteoporosis, fractures, and low BMD were highly prevalent from a young age in children and adolescents with DMD and increased progressively with age and GC exposure. The prevalence of osteoporosis reflected the cumulative acquisition of vertebral fractures, consistent with long-term GC effect. These data highlight the urgent need to improve early detection and prevention of osteoporosis in individuals with DMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.